Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2024
-
Canoo Acquires Manufacturing Assets to Increase Vehicle Assembly Capacity
-
ProMIS Neurosciences Issues Letter to Shareholders
-
Bitfarms Appoints Tracy Krumme as Senior Vice President, Head of Investor Relations
-
Travere Therapeutics Provides Corporate Update and 2024 Outlook
-
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients with Dry Eye Disease
-
Five Below, Inc. Announces Holiday Sales Results for Quarter-To-Date Through January 6, 2024
-
Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients
-
Treace Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2023 Revenue
-
CN Announces Remi G. Lalonde as Executive Vice-President
-
Hydreight Provides Year-End Review on Significant Growth and Progress
-
Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update
-
Solaris Provides 2024 Preview Including Planned NYSE American Listing and Updated Warintza Mineral Resource Estimate in Q2/24
-
Be The Match® Affirms Global Leadership in Life-saving Cell Therapies with New Name, Brand: NMDP℠
-
Tourmaline Bio Announces Expected Upcoming Key Milestones for the Clinical Development of TOUR006, a Long-Acting Subcutaneous Inhibitor of IL-6 with Best-in-Class Potential, in Thyroid Eye Disease (TE
-
Avadel Pharmaceuticals Announces Strong LUMRYZ Launch Performance and Provides Preliminary Fourth Quarter and Full Year 2023 Financial Highlights
-
Destination XL Group, Inc. Reports Holiday Sales Results
-
Absci to Present Preclinical Data for ABS-101, A Potential Best-in-Class Anti-TL1A Antibody Development Program, at 42nd Annual J.P. Morgan Healthcare Conference
-
Foghorn Therapeutics Highlights Clinical Program Updates and Research Progress and Provides Strategic Objectives for 2024
-
Cabaletta Bio Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis
-
iTeos Announces 2024 Strategic Priorities and Anticipated Milestones
-
CRAWFORD UNITED ACQUIRES HEANY INDUSTRIES
-
HilleVax and Kangh Announce Exclusive License Agreement for Hexavalent VLP Norovirus Vaccine Candidate Outside of China
-
PepGen Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of PGN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skipping
-
Akoustis to Attend the 26th Annual Needham Growth Conference on January 16, 2024
-
Dave Ramsey Hosts Break the Cycle: Stop Living Paycheck to Paycheck Free Livestream Event January 11
-
Abercrombie & Fitch Co. Increases Fourth Quarter Sales and Operating Margin Outlook Based on Better-Than-Expected Holiday Sales
-
LSL Pharma Group Announces an Extension of its Convertible Debentures Offering
-
OTC Markets Group Welcomes Westgold Resources Limited to OTCQX
-
Mural Oncology Announces Enhancements to Late-Stage Clinical Trials
-
MT Højgaard Holding A/S: MT Højgaard Property Development sells business project in Copenhagen’s South Harbour
-
Changes in the Supervisory and Management Board of Admirals Group AS
-
G1 Therapeutics Provides Corporate Update at the 42nd Annual J.P. Morgan Healthcare Conference
-
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
-
Asensus Surgical Provides Preliminary 2023 Year-End Corporate Update
-
HSBC Bank PLC: Pre Stabilisation Notice
-
INVESTOR DEADLINE NEXT WEEK: Robbins Geller Rudman & Dowd LLP Announces that NuScale Power Corporation Investors with Substantial Losses Have Opportunity to Lead Case - SMR
-
SpringWorks Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference
-
Cellectar Biosciences Announces Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom’s Macroglobulinemia
-
CalAmp Appoints Chris Adams as President and Chief Executive Officer
-
Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones
-
Hut 8 receives court approval in its stalking horse bid for four natural gas power plants including the North Bay Bitcoin mine
-
Transactions in connection with share buyback programme
-
DSM: Net Asset Value(s)
-
IHT DECLARES 54TH CONSECUTIVE ANNUAL DIVIDEND AS REVENUES CONTINUE TO CLIMB WITH RECORD DECEMBER
-
Parsons Secures $21 Million Task Order to Advance NNSA Infrastructure
-
Share repurchase programme
-
California Department of Insurance Approves Verisk's ISO Wildfire Mitigation Filings for Homeowners, Dwelling, Commercial Property, Commercial Inland Marine and Businessowners Programs
-
California Department of Insurance Approves Verisk's ISO Wildfire Mitigation Filings for Homeowners, Dwelling, Commercial Property, Commercial Inland Marine and Businessowners Programs
-
Novo Nordisk A/S - share repurchase programme
